Geron Corp (GERN):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Geron Corp (GERN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C9978)・商品コード:DATA904C9978
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:51
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Geron Corp (Geron) is a clinical stage biopharmaceutical company, which develops a telomerase inhibitor as a potential treatment for cancer. The company is evaluating its flagship product candidate Imetelstat in two clinical trials: IMbark and IMerge in partnership with Janssen Biotech, Inc. IMbark is a Phase II, randomized, single-blind and multi-center study for patients with high risk myelofibrosis (MF) whose disease is relapsed after or refractory to JAK inhibitor treatment; and IMerge is a Phase 2/3, multi-center study of imetelstat in transfusion-dependent participants with low or intermediate-1 risk myelodysplastic syndrome (MDS). Geron also has collaboration and royalty agreements with companies in oncology, diagnostics, biologics and research tools production domains. Geron is headquartered in Menlo Park, California, the US.

Geron Corp (GERN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Geron Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Geron Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Geron Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Geron Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Geron Corp, Medical Devices Deals, 2012 to YTD 2018 9
Geron Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Geron Corp, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Geron Enters into Licensing Agreement with Janssen Pharmaceuticals for RNA Interference 11
GE Healthcare Expands Licensing Agreement With Geron For Stem Cell Assays 12
Equity Offering 13
Geron Plans to Raise up to USD250 Million in Public Offering of Securities 13
Geron to Raise up to USD100 Million in Public Offering of Shares 14
Geron Plans to Raise up to USD50 Million in Public Offering of Shares 15
Geron Completes Public Offering Of Shares For US$103.5 Million 16
Geron Announces Public Offering Of Shares For Up To US$50 Million 18
Asset Transactions 19
BioTime Completes Acquisition Of Stem Cell Assets From Geron 19
Geron Corp – Key Competitors 21
Geron Corp – Key Employees 22
Geron Corp – Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Financial Announcements 24
Nov 01, 2018: Geron reports third quarter 2018 financial results and recent company events 24
Jul 31, 2018: Geron Reports Second Quarter 2018 Financial Results and Recent Company Events 26
May 10, 2018: Geron Reports First Quarter 2018 Financial Results 28
Mar 16, 2018: Geron Reports Fourth Quarter and Annual 2017 Financial Results and Recent Events 29
Nov 01, 2017: Geron Reports Third Quarter 2017 Financial Results 31
Aug 09, 2017: Geron Reports Second Quarter 2017 Financial Results 32
May 09, 2017: Geron Reports First Quarter 2017 Financial Results and Recent Events 33
Mar 01, 2017: Geron Reports Fourth Quarter and Annual 2016 Financial Results 35
Product News 37
12/12/2017: Geron Reports Imetelstat Presentations at American Society of Hematology Annual Meeting 37
11/01/2017: Janssen to Present Abstracts on Imetelstat at ASH 2017 39
06/18/2018: Geron Reports Imetelstat Oral Presentation at European Hematology Association Congress 41
05/17/2018: Geron Announces Oral Presentation at European Hematology Association Congress 43
Clinical Trials 44
Nov 20, 2017: Geron Announces First Patient Dosed in Expanded Part 1 of IMerge Clinical Trial in Myelodysplastic Syndromes 44
Oct 31, 2017: Geron Announces Fast Track Designation Granted to Imetelstat for Lower Risk Myelodysplastic Syndromes 45
Jul 31, 2017: Geron Announces Updates to Imetelstat Clinical Development 46
Apr 10, 2017: Geron Announces Completion of Second Internal Data Reviews for Imetelstat Trials Being Conducted by Janssen 47
Apr 05, 2017: Geron Reports Imetelstat Presentation at American Association for Cancer Research Annual Meeting 49
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50

List of Tables
Geron Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Geron Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Geron Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Geron Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Geron Corp, Deals By Therapy Area, 2012 to YTD 2018 9
Geron Corp, Medical Devices Deals, 2012 to YTD 2018 10
Geron Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Geron Enters into Licensing Agreement with Janssen Pharmaceuticals for RNA Interference 12
GE Healthcare Expands Licensing Agreement With Geron For Stem Cell Assays 13
Geron Plans to Raise up to USD250 Million in Public Offering of Securities 14
Geron to Raise up to USD100 Million in Public Offering of Shares 15
Geron Plans to Raise up to USD50 Million in Public Offering of Shares 16
Geron Completes Public Offering Of Shares For US$103.5 Million 17
Geron Announces Public Offering Of Shares For Up To US$50 Million 19
BioTime Completes Acquisition Of Stem Cell Assets From Geron 20
Geron Corp, Key Competitors 22
Geron Corp, Key Employees 23

List of Figures
Geron Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Geron Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Geron Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Geron Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Geron Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Geron Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Geron Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Geron Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Geron Corp, Medical Devices Deals, 2012 to YTD 2018 10

★調査レポート[Geron Corp (GERN):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C9978)販売に関する免責事項を必ずご確認ください。
★調査レポート[Geron Corp (GERN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆